PMID- 37391112
OWN - NLM
STAT- MEDLINE
DCOM- 20230809
LR  - 20230809
IS  - 1873-7528 (Electronic)
IS  - 0149-7634 (Linking)
VI  - 152
DP  - 2023 Sep
TI  - Clinical insights into the cross-link between mood disorders and type 2 diabetes: 
      A review of longitudinal studies and Mendelian randomisation analyses.
PG  - 105298
LID - S0149-7634(23)00267-1 [pii]
LID - 10.1016/j.neubiorev.2023.105298 [doi]
AB  - Mood disorders and type 2 diabetes mellitus (T2DM) are prevalent conditions that 
      often co-occur. We reviewed the available evidence from longitudinal and 
      Mendelian randomisation (MR) studies on the relationship between major depressive 
      disorder (MDD), bipolar disorder and T2DM. The clinical implications of this 
      comorbidity on the course of either condition and the impact of antidepressants, 
      mood stabilisers, and antidiabetic drugs were examined. Consistent evidence 
      indicates a bidirectional association between mood disorders and T2DM. T2DM leads 
      to more severe depression, whereas depression is associated with more 
      complications and higher mortality in T2DM. MR studies demonstrated a causal 
      effect of MDD on T2DM in Europeans, while a suggestive causal association in the 
      opposite direction was found in East Asians. Antidepressants, but not lithium, 
      were associated with a higher T2DM risk in the long-term, but confounders cannot 
      be excluded. Some oral antidiabetics, such as pioglitazone and liraglutide, may 
      be effective on depressive and cognitive symptoms. Studies in multi-ethnic 
      populations, with a more careful assessment of confounders and appropriate power, 
      would be important.
CI  - Copyright (c) 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.
FAU - Possidente, Chiara
AU  - Possidente C
AD  - Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, 
      Italy.
FAU - Fanelli, Giuseppe
AU  - Fanelli G
AD  - Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, 
      Italy; Department of Human Genetics, Radboud University Medical Center, Donders 
      Institute for Brain, Cognition and Behaviour, Nijmegen, the Netherlands.
FAU - Serretti, Alessandro
AU  - Serretti A
AD  - Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, 
      Italy. Electronic address: alessandro.serretti@unibo.it.
FAU - Fabbri, Chiara
AU  - Fabbri C
AD  - Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, 
      Italy; Social, Genetic & Developmental Psychiatry Centre, Institute of 
      Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230628
PL  - United States
TA  - Neurosci Biobehav Rev
JT  - Neuroscience and biobehavioral reviews
JID - 7806090
RN  - 0 (Hypoglycemic Agents)
RN  - X4OV71U42S (Pioglitazone)
SB  - IM
MH  - Humans
MH  - *Diabetes Mellitus, Type 2/complications
MH  - Mood Disorders/drug therapy/complications
MH  - *Depressive Disorder, Major/drug therapy
MH  - Hypoglycemic Agents/therapeutic use
MH  - Pioglitazone
OTO - NOTNLM
OT  - Depression
OT  - Glucagon-like peptide-1 (GLP-1) receptor agonists
OT  - Glycaemic control
OT  - Insulin resistance
OT  - Metformin
OT  - Mood stabilisers
OT  - Non-insulin-dependent diabetes
OT  - Oral hypoglycaemics
OT  - Pioglitazone
OT  - Selective serotonin reuptake inhibitors
OT  - Thiazolidinediones
OT  - Treatment resistance
COIS- Declarations of interest AS is or has been consultant/speaker for Abbott, Abbvie, 
      Angelini, AstraZeneca, Clinical Data, Boheringer, Bristol-Myers Squibb, Eli 
      Lilly, GlaxoSmithKline, Innovapharma, Italfarmaco, Janssen, Lundbeck, Naurex, 
      Pfizer, Polifarma, Sanofi, and Servier. CF was a speaker for Janssen. The other 
      authors declare no potential conflicts of interest.
EDAT- 2023/07/01 11:41
MHDA- 2023/08/09 06:43
CRDT- 2023/06/30 19:17
PHST- 2022/12/21 00:00 [received]
PHST- 2023/05/15 00:00 [revised]
PHST- 2023/06/26 00:00 [accepted]
PHST- 2023/08/09 06:43 [medline]
PHST- 2023/07/01 11:41 [pubmed]
PHST- 2023/06/30 19:17 [entrez]
AID - S0149-7634(23)00267-1 [pii]
AID - 10.1016/j.neubiorev.2023.105298 [doi]
PST - ppublish
SO  - Neurosci Biobehav Rev. 2023 Sep;152:105298. doi: 10.1016/j.neubiorev.2023.105298. 
      Epub 2023 Jun 28.